Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.

Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J.

Int J Cardiol. 2013 Oct 3;168(3):2540-7. doi: 10.1016/j.ijcard.2013.03.059. Epub 2013 May 8.

PMID:
23664436
2.

Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.

Chevalier J, Giroud M, de Pouvourville G.

Cerebrovasc Dis. 2013;35(4):320-6. doi: 10.1159/000347074. Epub 2013 Apr 23.

PMID:
23615428
3.

Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.

Ho JC, Chang AM, Yan BP, Yu CM, Lam YY, Lee VW.

Clin Cardiol. 2012 Dec;35(12):E40-5. doi: 10.1002/clc.22069. Epub 2012 Oct 25.

4.

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.

Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ.

Circulation. 2012 Feb 7;125(5):669-76. doi: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3.

5.

Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.

Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S.

J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042. Epub 2013 Jun 13.

6.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.

Chevalier J, Delaitre O, Hammès F, de Pouvourville G.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

7.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators.

Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.

PMID:
22084332
8.

Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.

Atay JK, Fanikos J, Barnes GD, Ehle M, Coatney J, Piazza G, Froehlich JB, Goldhaber SZ.

Am J Cardiol. 2013 Aug 1;112(3):387-9. doi: 10.1016/j.amjcard.2013.03.046. Epub 2013 May 3.

PMID:
23647794
9.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
10.

Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.

Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY.

Thromb Haemost. 2013 Feb;109(2):328-36. doi: 10.1160/TH12-08-0539. Epub 2012 Nov 22.

PMID:
23179181
11.

Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.

Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74. doi: 10.1161/CIRCOUTCOMES.113.000192. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e59.

12.

Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.

Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, Fraessdorf M, Reilly PA, Yusuf S, Wallentin L; RE-LY Investigators.

Eur J Heart Fail. 2013 Sep;15(9):1053-61. doi: 10.1093/eurjhf/hft111. Epub 2013 Jul 9.

13.

[Expectation to and problems of thrombin inhibitor].

Uchiyama S.

Rinsho Shinkeigaku. 2011 Nov;51(11):1004-6. Japanese.

PMID:
22277458
14.

Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.

Ali A, Bailey C, Abdelhafiz AH.

Age Ageing. 2012 Sep;41(5):681-4. doi: 10.1093/ageing/afs017. Epub 2012 Feb 28.

PMID:
22378612
15.

Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.

Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Lane DA, Lip GY.

Am J Med. 2014 Dec;127(12):1172-8.e5. doi: 10.1016/j.amjmed.2014.07.023. Epub 2014 Sep 1.

PMID:
25193361
16.

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.

Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S.

Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.

17.

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.

Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.

18.

Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.

Hong C, Kim S, Curnew G, Schulman S, Pullenayegum E, Holbrook A.

J Popul Ther Clin Pharmacol. 2013;20(3):e229-37. Epub 2013 Sep 6.

PMID:
24163147
19.

Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.

Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, Mansour MC, D'Avila A, Sanchez JE, Burkhardt JD, Chalhoub F, Mohanty P, Coffey J, Shaik N, Monir G, Reddy VY, Ruskin J, Natale A.

J Am Coll Cardiol. 2012 Mar 27;59(13):1168-74. doi: 10.1016/j.jacc.2011.12.014. Epub 2012 Feb 1.

20.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

Supplemental Content

Support Center